Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacia execs

This article was originally published in The Tan Sheet

Executive Summary

CEO Fred Hassan advises Pfizer he will not join firm's Board of Directors as vice chairman, Pfizer announces April 14. With Federal Trade Commission approval of merger of Pharmacia with Pfizer occurring the same day, Hassan says he plans to "pursue other career opportunities" later this month. Hassan is said to be a front runner for the CEO post at Schering-Plough (1"The Tan Sheet" April 7, 2003, p. 10). Separately, Pharmacia R&D President Goran Ando will leave the company to serve as CEO for UK biotech firm Celltech...

You may also be interested in...

Schering CEO Selection Being Closely Watched By Investors

Schering-Plough's appointment of a new CEO, following the retirement of Richard Kogan later this month, could steady the firm's share price and help it weather what is expected to be a difficult year

Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts